Drug and radiation therapy for recurrent salivary gland cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This study tests a combination of a targeted cancer drug (antibody-drug conjugate) and focused radiation therapy for salivary gland cancers that have come back or spread after initial treatment. It may help patients whose cancer didn't respond to standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with salivary gland cancer (head and neck) that has returned or spread, confirmed by biopsy or imaging
- Disease progressed after first-line treatment or you're not able to receive standard therapy
- At least one measurable tumor visible on imaging scans
- Good overall health with ability to care for yourself (ECOG score 0–1)
- Normal or near-normal blood counts, liver, and kidney function
- Expected to live at least 6 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests a new cancer drug called sacituzumab tirumotecan (a targeted antibody-drug) in patients with adenoid cystic carcinoma or papillary thyroid cancer that has spread or cannot be surgically removed. The drug is designed to find and attack cancer cells while minimizing harm to healthy cells.
This study tests giving radiation and chemotherapy together after surgery for aggressive salivary gland cancers of the head and neck. It aims to see how well this standard treatment works in real-world settings.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
Hear when a new SBRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.